BiotechTube
Surge

Surge

San Francisco, United States· Est.
surge.care
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $32M

Overview

SurgeCare is a San Francisco-based biotech company founded in 2020, developing an AI-powered platform for immune biomarker discovery. Its core technology, Stabl, is a multiomics and machine learning algorithm designed to extract robust biological 'fingerprints' from complex datasets to predict clinical outcomes. The company's first commercial product line, PreCyte, focuses on predicting surgical complications, with an initial launch in the United States. Surge is backed by a team with strong academic pedigrees and has secured partnerships and investment from notable European and U.S. entities.

Surgical ComplicationsInfectionTrauma

Technology Platform

Stabl: A proprietary machine learning algorithm for multiomic data analysis that extracts robust, interpretable biological 'fingerprints' to discover predictive biomarkers for clinical applications.

Funding History

1
Total raised:$32M
Venture$32M

Opportunities

The global push towards value-based care creates a strong tailwind for predictive tools that reduce costly hospital complications.
Furthermore, the platform-agnostic nature of Surge's Stabl technology allows for rapid expansion into new disease areas beyond surgery, such as sepsis, oncology, and autoimmune disorders, and enables lucrative partnerships with therapeutic developers.

Risk Factors

Key risks include the challenge of integrating a new diagnostic tool into complex hospital workflows and securing reimbursement.
The company also faces competition from both large diagnostic firms and nimble AI startups, and must continuously validate its biomarkers in diverse real-world clinical settings to maintain scientific and commercial credibility.

Competitive Landscape

Surge operates in the competitive AI-driven biomarker discovery and predictive diagnostics space. It faces competition from large, established diagnostic companies (e.g., Roche, Abbott) investing in digital health, as well as from a growing cohort of venture-backed startups focused on computational pathology or multiomic analysis. Surge's differentiation lies in its specific focus on immune system 'fingerprinting' and its foundational research in perioperative immunology.

More companies in AI / Machine Learning →More companies in United States →